Abstract
Disorders of lipoprotein and lipid metabolism—dyslipidemias—can be classified based on the primary biochemical disturbance, such as high or low plasma levels of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, or some combination of these. Several monogenic dyslipidemias, such as heterozygous familial hypercholesterolemia, are now defined at the molecular genetic level. To prevent serious complications, particularly premature cardiovascular disease, in monogenic dyslipidemias it is important to screen subjects at risk. Diagnosis may require clinical, biochemical and genomic DNA assessment. Treatment includes diet, exercise and lipid-lowering medications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Emery and Rimoin's Principles and Practice of Medical Genetics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
